ANGO · Insider Trading
AngioDynamics, Inc.
Every open-market purchase and sale reported by ANGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Warren Nighan JR | SVP Quality and Regulatory | Sell | −23,370 | −$344.01K |
| 2026-07-24 | Chad Thomas Campbell | SVP/GM, Vascular Access | MIXED | +4,136 | −$32.20K |
| 2026-07-24 | Laura Piccinini | SVP International | MIXED | +3,541 | −$62.27K |
| 2026-07-24 | James C Clemmer | President and CEO | MIXED | +25,630 | −$369.38K |
| 2026-07-24 | Stephen A Trowbridge | EVP and CFO | MIXED | +7,977 | −$114.97K |
| 2026-07-24 | Warren Nighan JR | SVP Quality and Regulatory | MIXED | +4,023 | −$23.09K |
| 2026-07-22 | Wesley Johnson | Director | A | +11,887 | — |
| 2026-07-22 | Michael E Tarnoff | Director | A | +11,887 | — |
| 2026-07-22 | Stephen A Trowbridge | EVP and CFO | A | +53,257 | — |
| 2026-07-22 | Lawrence T Weiss | SVP, Chief Legal Officer | A | +21,288 | — |
| 2026-07-22 | Warren Nighan JR | SVP Quality and Regulatory | A | +17,966 | — |
| 2026-07-22 | Eileen O'Shea Auen | Director | A | +11,887 | — |
| 2026-07-22 | Chad Thomas Campbell | SVP/GM, Vascular Access | A | +16,081 | — |
| 2026-07-22 | Howard W Donnelly | Director | A | +11,887 | — |
| 2026-07-22 | Lorinda Burgess | Director | A | +11,887 | — |
| 2026-07-22 | Jan Stern Reed | Director | A | +11,887 | — |
| 2026-07-22 | Laura Piccinini | SVP International | A | +19,860 | — |
| 2026-07-22 | Karen A Licitra | Director | A | +11,887 | — |
| 2026-07-21 | Warren Nighan JR | SVP Quality and Regulatory | F | −3,777 | −$52.43K |
| 2026-07-21 | Lawrence T Weiss | SVP, Chief Legal Officer | F | −2,267 | −$32.06K |
| 2026-07-21 | Chad Thomas Campbell | SVP/GM, Vascular Access | F | −3,838 | −$53.41K |
| 2026-07-21 | Laura Piccinini | SVP International | F | −8,228 | −$114.14K |
| 2026-07-21 | Stephen A Trowbridge | EVP and CFO | F | −12,067 | −$168.11K |
| 2026-07-21 | James C Clemmer | President and CEO | F | −45,711 | −$630.11K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James C Clemmer | President and CEO | 862,448 | $10.50M |
| Stephen A Trowbridge | EVP and CFO | 314,115 | $3.82M |
| Howard W Donnelly | Director | 178,938 | $2.18M |
| Wesley Johnson | Director | 155,425 | $1.89M |
| Jan Stern Reed | Director | 116,921 | $1.42M |
| Eileen O'Shea Auen | Director | 116,605 | $1.42M |
| Lawrence T Weiss | SVP, Chief Legal Officer | 112,618 | $1.37M |
| Chad Thomas Campbell | SVP/GM, Vascular Access | 108,676 | $1.32M |
| Karen A Licitra | Director | 102,322 | $1.25M |
| Michael E Tarnoff | Director | 95,265 | $1.16M |
| Laura Piccinini | SVP International | 86,435 | $1.05M |
| Lorinda Burgess | Director | 67,144 | $817.14K |
| Warren Nighan JR | SVP Quality and Regulatory | 64,745 | $787.95K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANGO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.